Investigational Studies

LONDON, Feb. 08, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin Gover, GW’s Chief Executive Officer, will present at the Leerink Partners 6th Annual Global Healthcare Conference on Wednesday, February […]

by

– Epidiolex® NDA submission and launch preparation on track –– New Positive Phase 2 glioma data further demonstrates value of cannabinoid pipeline – – Conference call today at 8:30 a.m. EST – LONDON, Feb. 07, 2017 — GW Pharmaceuticals plc (NASDAQ:GWPH) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing […]

by

GW intends to advance oncology research and development efforts London (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced positive top-line results from an exploratory Phase 2 placebo-controlled clinical study of a […]

by

GW Pharmaceuticals Achieves Positive Results in Phase 2 Proof of Concept Study in Glioma GW intends to advance oncology research and development efforts LONDON, Feb. 07, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused… read more at: https://www.newcannabisventures.com/gw-pharma-reports-success-in-brain-cancer-phase-2-clinical-trial/

by

February 3, 2017 (Investorideas.com Newswire) Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks, releases a second excerpt of its current cannabis /hemp stock directory for investors following the sector. According to a report from Research and Markets, The global legal marijuana market to grow at a CAGR of 37.38% during […]

by

Related SectorsContract Research Services Clinical Trials Related Dates2017 January Related IndustriesPharmaceuticals and Healthcare Services Outsourced Services Contract Research Organization Clinical trials … read more at: http://clinicaltrials.pharmaceutical-business-review.com/news/zynerba-starts-phase-2-trial-of-zyn002-in-fragile-x-syndrome-040117-5708907

by

Editorial: Steve McIver, EditorAdvertising: Maureen Dwyer Liberti, Vice President, Group PublisherProduction: Dawn Flook, Director of Production ServicesCirculation: Jackie Ott, Circulation ManagerWebmaster: Webmaster … read more at: https://www.ptcommunity.com/wire/gw-pharmaceuticals-report-q1-financial-results-and-host-conference-call-7-february-2017

by

Editorial: Steve McIver, EditorAdvertising: Maureen Dwyer Liberti, Vice President, Group PublisherProduction: Dawn Flook, Director of Production ServicesCirculation: Jackie Ott, Circulation ManagerWebmaster: Webmaster … read more at: https://www.ptcommunity.com/wire/gw-pharmaceuticals-report-q1-financial-results-and-host-conference-call-7-february-2017

by

LONDON, Jan. 30, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 7 February, 2017 its first quarter financial results for the period ending 31 December, 2016. GW will also host a […]

by

Kalytera Therapeutics Inc has entered into a binding letter of intent (LOI) to acquire Talent Biotechs Ltd, an Israeli-based developer of proprietary cannabidiol (CBD) therapeutics. Currently, Talent is advancing a phase 2 clinical program examining the use of CBD to prevent and treat Graft versus Host Disease (GvHD), according to a press release. GvHD is […]

by

Kalytera enters into binding letter of intent to acquire Talent Biotechs and its Phase 2 clinical-stage Graft versus Host Disease program. Kalytera Therapeutics, Inc. has entered into a binding letter of intent (LOI) to acquire all of the issued and outstanding securities of Talent Biotechs Ltd., a privately held, Israeli-based developer of proprietary cannabidiol (CBD) […]

by